Please assess the completion status of the following clinical trial:

Trial Title: Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with IRD receiving active anti-rheumatic treatments with DMARDs or biological remedies are offered to participate in the study. The protocol permits stratification for prednisolone usage, smoking habits and alcohol consumption.~Exclusion Criteria:~* age \<18 years;~* pregnancy,~* known intolerance of vaccine,~* ongoing infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- vaccinated patients (Type: ACTIVE_COMPARATOR): patients with different inflammatory rheumatic disease immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
- vaccinated controls (Type: ACTIVE_COMPARATOR): healthy controls immunized with 0,5 mg pneumococcal conjugate vaccine i.m.
- seasonal influenza vaccine (Type: ACTIVE_COMPARATOR): patients with different inflammatory rheumatic diseases immunized with 0,5 mg seasonal influenza vaccine i.m.
- non-vaccinated controls (Type: ACTIVE_COMPARATOR): healthy controls immunized with 0,5 mg seasonal influenza vaccine i.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).